Myriad Genetics (MYGN) – Press Releases
-
Nearly Half of Americans Say They’ve Lost Time in Their Lives Due to Poor Mental Health, According to the GeneSight Mental Health Monitor
-
New Myriad Genetics Study Published in Prenatal Diagnosis Shows High Positive Predictive Value for 22q11.2 Microdeletion Syndrome Using Prequel® Prenatal Screen
-
Myriad Genetics Research Shows Reduction in Hospitalizations for Patients with Depression after GeneSight Testing
-
Myriad Genetics Announces Foundational Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date
-
Myriad Genetics Announces Patent Granted for SneakPeek® Snap Device
-
Myriad Genetics Reports Strong Fourth Quarter and Full-Year 2023 Financial Results; Fourth Quarter Revenue of $197 Million and Full-Year Revenue of $753 Million Each Grew 11% Year-Over-Year; Delivered
-
Myriad Genetics and National Cancer Center Hospital East in Japan Collaborate on Pan-Cancer MRD Monitoring Clinical Trial, SCRUM-MONSTAR-SCREEN-3
-
Myriad Genetics to Release Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024
-
Myriad Genetics Appoints Dallas Reed, MD, FACOG, FACMG as Principal Medical Advisor of Women’s Health
-
Myriad Genetics Completes Acquisition of Precise Tumor, Precise Liquid and Laboratory from Intermountain Precision Genomics
-
Myriad Genetics Names George Daneker Jr., MD, as President and Chief Clinical Officer of Oncology
-
Myriad Genetics to Acquire Precise Tumor, Precise Liquid and Laboratory from Intermountain Precision Genomics
-
Myriad Genetics Applauds New Germline Testing Guideline for Patients with Breast Cancer from ASCO-SSO
-
Myriad Genetics to Present at 42nd Annual J.P. Morgan Healthcare Conference
-
Myriad Genetics Chief Financial Officer Bryan Riggsbee Retires; Scott Leffler Appointed as Successor; Reiterates Previously Issued Financial Guidance
-
Myriad Genetics Establishes Comprehensive Pan-Cancer Research Platform to Advance Patient Care
-
Myriad Genetics Celebrates One Million SneakPeek® Results Shared with Expectant Parents
-
Myriad Genetics and Personalis Partner to Market Solutions to Pharma Customers
-
Myriad Genetics to Participate in Stephens Annual Investment Conference
-
Myriad Genetics Announces Pricing of Upsized Offering of Common Stock
-
Myriad Genetics Announces Proposed Offering of $100 Million of Shares of Common Stock
-
Myriad Genetics Reports Third Quarter 2023 Financial Results; Generates Double-Digit Revenue Growth; Raises 2023 Revenue Guidance and Introduces 2024 Revenue Guidance
-
Myriad Genetics Appoints Sam Raha as Chief Operating Officer
-
Myriad Genetics to Release Third Quarter Financial Results on November 6, 2023
-
QIAGEN and Myriad Genetics partner to advance companion diagnostics development for cancer
-
BREAST CANCER AWARENESS MONTH: NEW CANCER RISK SURVEY REVEALS RISK FACTORS ARE WIDELY MISUNDERSTOOD
-
New Myriad Genetics Survey Shows Breast Cancer Risk Factors Are Misunderstood
-
Myriad Genetics and Illumina Achieve Milestones in Strategic Partnership to Support Biopharma Clinical Trials
-
Myriad Genetics Issues 2022 Environmental, Social and Governance Report
-
Myriad Genetics and Leading Cancer Center Collaborate to Study the Use of Minimal Residual Disease Testing in Breast Cancer
-
Myriad Genetics Named to 2023 Best Workplaces in Health Care List by Fortune and Great Place To Work
-
New Myriad Genetics Survey Reveals Widespread Confusion and Misconceptions About Ovarian Cancer Screening Among a Majority of Women
-
Myriad Genetics to Participate in Morgan Stanley Global Healthcare Conference
-
Myriad Genetics and Onsite Women’s Health Partner to Help More Women Understand Breast Cancer Risk
-
Myriad Genetics to Host Investor Day on September 19, 2023
-
Myriad Genetics Advances Prostate Cancer Care with Addition of Absolute Risk Reduction to Prolaris®
-
Myriad Genetics and Intermountain Health Participate in ComboMATCH, a National Clinical Trial to Advance Cancer Treatment
-
Myriad Genetics Announces Enhancements to the GeneSight® Test to Personalize Mental Health Medication Treatment Decisions Based on Smoking Status
-
Myriad Genetics Reports Second Quarter 2023 Financial Results and Reaffirms 2023 Revenue and Adjusted EPS Guidance; Generates the Fourth Consecutive Quarter of Double-Digit Year-Over-Year Testing Volu
-
Myriad Genetics to Release Second Quarter Financial Results on Aug. 3, 2023
-
Myriad Genetics Announces Inclusion of Breast Density to MyRisk® with RiskScore® Breast Cancer Risk Assessment
-
Myriad Genetics Announces New $90 Million Asset-Based Credit Facility
-
Myriad Genetics Announces Research Collaboration to use Minimal Residual Disease Testing Platform
-
Myriad Genetics to Participate in Goldman Sachs Healthcare Conference
-
Myriad Genetics Highlights Latest Oncology Portfolio Advancements and New Data at ASCO 2023
-
Adam Brufsky, MD, PhD, FACP Named Oncology Scientific Advisor to Myriad Genetics
-
Myriad Genetics Adds Folate Receptor Alpha to Precise™ Oncology Solutions Portfolio to Expand Treatment Options for Women Living with Ovarian Cancer
-
Myriad Genetics Earns 2023 Great Place to Work Certification™
-
Myriad Genetics Reports First Quarter 2023 Financial Results; Achieves 10% Revenue Growth Year-Over-Year, the Second Consecutive Quarter of Double-Digit Year-Over-Year Revenue Growth; Raises Mid-Point
-
Myriad Genetics to Participate in BofA Securities Healthcare Conference
Back to MYGN Stock Lookup
